Triple
T9807399
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | programmed death-ligand 1 |
E238185
|
entity |
| Predicate | targetOfDrug |
P37016
|
FINISHED |
| Object |
nivolumab
Nivolumab is a monoclonal antibody immunotherapy drug that blocks the PD-1 immune checkpoint to enhance the body’s anti-tumor response in various cancers.
|
E824658
|
NE FINISHED |
Provenance (5 batches)
| Stage | Batch ID | Job type | Status |
|---|---|---|---|
| creating | batch_69ca84defac48190abc1148804f184c1 |
elicitation | completed |
| NER | batch_69cdab7ddaac8190a5584a5c863fbaa3 |
ner | completed |
| NED1 | batch_69d1d5aecdec81909fae349945406c6c |
ned_source_triple | completed |
| NED2 | batch_69d1d6dc0bd8819082a5ad417ca87a76 |
ned_description | completed |
| NEDg | batch_69d1d6463fe481908e5d3f3fd22cffa4 |
nedg | completed |
Created at: March 30, 2026, 8:29 p.m.